Jazz Pharmaceuticals (JAZZ) Valuation After HERIZON GEA Trial Upside And Planned 2026 sBLA Filing

Jazz Pharmaceuticals (NasdaqGS:JAZZ) is back in focus after practice changing HERIZON GEA trial results and plans to file a supplemental Biologics License Application in 2026 for first line gastroesophageal adenocarcinoma therapies.

See our latest analysis for Jazz Pharmaceuticals.

Investors have responded positively to the HERIZON GEA update, with a 24.26% 90 day share price return from Jazz Pharmaceuticals and a 37.58% 1 year total shareholder return, suggesting momentum has picked up despite a year to date share price decline of 4.42% at a current price of $165.50.

If cancer and biologics news has your attention, it could be a good moment to scan other healthcare names through our screener of 26 healthcare AI stocks.

With Jazz reporting US$4,157.8m in revenue alongside a net loss of US$368.5m, mixed earnings trends, high leverage and a sizeable discount to analyst targets, you have to ask: is there real value here, or is the market already baking in future growth?

Most Popular Narrative: 22.3% Undervalued

With Jazz Pharmaceuticals last closing at $165.50 against a most followed fair value estimate of $213.00, the current setup puts the narrative front and center for anyone trying to make sense of that gap.

The expected approval and launches of multiple therapies (dordaviprone for H3 K27M mutant diffuse glioma and Zepzelca in first line maintenance for small cell lung cancer) are set to drive new revenue streams and capitalize on unmet needs in rare cancers, supporting topline growth and improved earnings consistency. Ongoing investments in R&D, commercialization infrastructure, and international launches (such as rolling out Ziihera in BTC across Europe) are lowering barriers to entry in new geographies as healthcare access expands. This is positioning Jazz for steady long term market share and revenue growth.

Read the complete narrative.

Curious what earnings path and margin profile sit behind that $213.00 figure? The narrative leans on a multi year ramp in profitability, a higher revenue run rate, and a future earnings multiple that differs from today. Want to see exactly how those assumptions stack up and what needs to go right for Jazz to close that valuation gap?

Result: Fair Value of $213 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, you still need to watch for patent expiries that invite generic competition in oxybate drugs, as well as the risk that key pipeline launches, like Ziihera, underwhelm expectations.

Find out about the key risks to this Jazz Pharmaceuticals narrative.

Build Your Own Jazz Pharmaceuticals Narrative

If you see Jazz’s story differently, or you just prefer to test the numbers yourself, you can build a custom view in minutes by starting with Do it your way.

A great starting point for your Jazz Pharmaceuticals research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you are serious about putting your capital to work, do not stop with one company when you can quickly filter dozens of ideas that fit your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com